SCYNEXIS, Inc. (SCYX)
USD 1.09
(12.36%)
USD 1.09
(12.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 67.04 Million USD | 206.74% |
| 2022 | -62.8 Million USD | -91.11% |
| 2021 | -32.86 Million USD | 40.44% |
| 2020 | -55.18 Million USD | 0.09% |
| 2019 | -55.23 Million USD | -343.01% |
| 2018 | -12.46 Million USD | 50.25% |
| 2017 | -25.06 Million USD | 16.44% |
| 2016 | -29.98 Million USD | 8.07% |
| 2015 | -32.62 Million USD | -670.5% |
| 2014 | -4.23 Million USD | 86.1% |
| 2013 | -30.46 Million USD | -165.41% |
| 2012 | -11.47 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 411 Thousand USD | 102.1% |
| 2024 Q2 | -14.45 Million USD | -3617.76% |
| 2023 Q2 | 122.26 Million USD | 319.8% |
| 2023 Q1 | -55.62 Million USD | -190.78% |
| 2023 FY | 67.04 Million USD | 206.74% |
| 2023 Q4 | -19.58 Million USD | -1014.74% |
| 2023 Q3 | -1.75 Million USD | -101.44% |
| 2022 Q3 | -37.17 Million USD | -178.59% |
| 2022 Q4 | -19.12 Million USD | 48.55% |
| 2022 Q1 | -5.45 Million USD | 81.36% |
| 2022 FY | -62.8 Million USD | -91.11% |
| 2022 Q2 | -13.34 Million USD | -144.82% |
| 2021 Q2 | 1.65 Million USD | 135.46% |
| 2021 Q1 | -4.67 Million USD | 89.05% |
| 2021 Q4 | -29.24 Million USD | -4733.55% |
| 2021 Q3 | -605 Thousand USD | -136.49% |
| 2021 FY | -32.86 Million USD | 40.44% |
| 2020 Q2 | -6.38 Million USD | 8.87% |
| 2020 Q3 | 909 Thousand USD | 114.25% |
| 2020 Q4 | -42.71 Million USD | -4798.68% |
| 2020 FY | -55.18 Million USD | 0.09% |
| 2020 Q1 | -7 Million USD | 51.57% |
| 2019 FY | -55.23 Million USD | -343.01% |
| 2019 Q1 | -22.9 Million USD | -1279.61% |
| 2019 Q3 | -7.94 Million USD | 5.5% |
| 2019 Q4 | -14.45 Million USD | -82.07% |
| 2019 Q2 | -8.4 Million USD | 63.32% |
| 2018 FY | -12.46 Million USD | 50.25% |
| 2018 Q4 | 1.94 Million USD | 453.28% |
| 2018 Q3 | 351 Thousand USD | 103.26% |
| 2018 Q2 | -10.75 Million USD | -168.79% |
| 2018 Q1 | -4 Million USD | 47.27% |
| 2017 Q1 | -4.86 Million USD | -41.17% |
| 2017 Q2 | -4.19 Million USD | 13.76% |
| 2017 Q3 | -8.4 Million USD | -100.07% |
| 2017 Q4 | -7.59 Million USD | 9.65% |
| 2017 FY | -25.06 Million USD | 16.44% |
| 2016 Q4 | -3.44 Million USD | 69.28% |
| 2016 Q1 | -7.18 Million USD | 14.35% |
| 2016 Q3 | -11.22 Million USD | -38.14% |
| 2016 Q2 | -8.12 Million USD | -13.14% |
| 2016 FY | -29.98 Million USD | 8.07% |
| 2015 Q2 | -9.49 Million USD | -48.76% |
| 2015 Q1 | -6.38 Million USD | -107.61% |
| 2015 FY | -32.62 Million USD | -670.5% |
| 2015 Q3 | -8.35 Million USD | 12.02% |
| 2015 Q4 | -8.38 Million USD | -0.39% |
| 2014 FY | -4.23 Million USD | 86.1% |
| 2014 Q2 | 2.23 Million USD | 441.99% |
| 2014 Q3 | -3.8 Million USD | -270.35% |
| 2014 Q4 | -3.07 Million USD | 19.16% |
| 2014 Q1 | 412 Thousand USD | 101.9% |
| 2013 Q3 | -3.96 Million USD | -46.5% |
| 2013 FY | -30.46 Million USD | -165.41% |
| 2013 Q4 | -21.72 Million USD | -448.71% |
| 2013 Q1 | -2.06 Million USD | 0.0% |
| 2013 Q2 | -2.7 Million USD | -30.64% |
| 2012 FY | -11.47 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 147.998% |
| PainReform Ltd. | -9.34 Million USD | 817.476% |
| Alvotech | -551.73 Million USD | 112.151% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | -39.219% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -257.0% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 951.855% |
| Journey Medical Corporation | -3.85 Million USD | 1839.969% |
| Dynavax Technologies Corporation | -6.38 Million USD | 1149.319% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 132.039% |
| Bright Green Corporation | -13.12 Million USD | 610.686% |
| Pacira BioSciences, Inc. | 41.95 Million USD | -59.793% |
| Embecta Corp. | 70.4 Million USD | 4.771% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 1587.802% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 1587.802% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 921.26% |
| Silver Spike Investment Corp. | 7.34 Million USD | -813.352% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 2263.637% |
| Alpha Teknova, Inc. | -36.78 Million USD | 282.276% |
| Safety Shot Inc | -15.08 Million USD | 544.479% |
| Procaps Group, S.A. | 42.54 Million USD | -57.595% |
| Cosmos Health Inc. | -18.54 Million USD | 461.55% |
| Theratechnologies Inc. | -23.95 Million USD | 379.839% |
| Harrow Health, Inc. | -24.41 Million USD | 374.634% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 1486.577% |
| Biofrontera Inc. | -20.13 Million USD | 433.024% |
| DURECT Corporation | -27.62 Million USD | 342.691% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -4994.301% |
| Cronos Group Inc. | -73.96 Million USD | 190.641% |
| OptiNose, Inc. | -35.48 Million USD | 288.938% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 106.689% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 258.869% |
| RedHill Biopharma Ltd. | 23.91 Million USD | -180.319% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -1255.733% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -42322.152% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 1167.647% |
| Radius Health, Inc. | -25.79 Million USD | 359.94% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 1187.787% |
| ProPhase Labs, Inc. | -16.78 Million USD | 499.482% |
| Phibro Animal Health Corporation | 2.41 Million USD | -2674.876% |
| Procaps Group S.A. | 42.54 Million USD | -57.595% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 752.277% |
| Viatris Inc. | 54.7 Million USD | -22.561% |
| Rockwell Medical, Inc. | -8.43 Million USD | 894.419% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 523.132% |
| SIGA Technologies, Inc. | 68.06 Million USD | 1.51% |
| Tilray Brands, Inc. | -244.98 Million USD | 127.366% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -458.07% |
| Shineco, Inc. | -22.44 Million USD | 398.637% |
| PetIQ, Inc. | 2.13 Million USD | -3045.988% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 1658.427% |
| Incannex Healthcare Limited | -18.45 Million USD | 463.189% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 73.151% |
| Alimera Sciences, Inc. | -20.13 Million USD | 433.007% |
| Assertio Holdings, Inc. | -331.94 Million USD | 120.197% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 1116.894% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 474.552% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 434.247% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 141.828% |
| Hempacco Co., Inc. | -13.12 Million USD | 610.747% |
| Talphera, Inc. | -18.39 Million USD | 464.413% |
| Alvotech | -551.73 Million USD | 112.151% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | -88.096% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 79.477% |
| Currenc Group, Inc. | -15.3 Million USD | 537.989% |
| Kamada Ltd. | 8.28 Million USD | -709.283% |
| Indivior PLC | 2 Million USD | -3252.05% |
| Evoke Pharma, Inc. | -7.79 Million USD | 960.35% |
| Flora Growth Corp. | -57.03 Million USD | 217.542% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 434.247% |
| Evolus, Inc. | -61.68 Million USD | 208.683% |
| HUTCHMED (China) Limited | 100.78 Million USD | 33.478% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 51.259% |
| Akanda Corp. | -32.27 Million USD | 307.718% |